Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Precision Exercise Using Myostatin/Follistatin Ratio in Obese Adults (PRECISION-MASL)

18 november 2026 bijgewerkt door: Diabetes Foundation, India

A Precision Exercise Approach Using Myostatin/Follistatin Ratio Stratification to Improve Lean Body Mass and Metabolic Health: A 12-Month Randomized Clinical Trial in Obese North Indian Adults

This study evaluates whether a 12-month supervised progressive resistance training program improves lean body mass and metabolic health in obese North Indian adults aged 35-60 years. Asian Indians are uniquely predisposed to sarcopenic obesity-the coexistence of excess body fat and reduced muscle mass-which significantly increases the risk of type 2 diabetes and cardiovascular disease.

Participants will be stratified into High-Ratio and Low-Ratio groups based on their baseline Myostatin/Follistatin (MSTN/FST) ratio, an biological index of muscle catabolism versus growth. Half of the participants in each stratum will undergo a 12-month supervised resistance training program, while the other half will receive standard lifestyle advice. The primary goal is to determine whether baseline MSTN/FST ratio predicts the extent of muscle mass gain and whether reducing this ratio mediates improvements in insulin resistance and systemic inflammation.

Studie Overzicht

Gedetailleerde beschrijving

Background & Scientific Rationale: Sarcopenic obesity is a major driver of cardiometabolic risk in Asian Indians due to low baseline lean mass combined with high visceral adiposity. Myostatin (MSTN) acts as a primary negative regulator of muscle growth, whereas follistatin (FST) acts as its circulating antagonist. Previous genetic research demonstrates that gain-of-function Myostatin gene variants are strongly associated with lower lean body mass and increased adiposity in North Indians. This trial prospectively tests whether the serum MSTN/FST ratio functions as a precision biomarker to stratify exercise response and guide targeted exercise interventions.

Study Objectives:

Determine the efficacy of a 12-month supervised resistance training program on total lean body mass (LBM) and physical performance compared to lifestyle control, testing for treatment interaction across baseline MSTN/FST strata.

Characterize the molecular adaptations of the myostatin axis by measuring serum myostatin, follistatin, MSTN/FST ratio, and peripheral blood mononuclear cell (PBMC) MSTN mRNA expression at baseline and 12 months.

Assess whether reductions in the MSTN/FST ratio mediate improvements in insulin resistance (HOMA-IR), systemic inflammatory markers (IL-6, TNF-α, hsCRP), and muscle quality.

Trial Design & Interventions: A single-center, ratio-stratified, 1:1 parallel-group randomized controlled superiority trial of 200 obese North Indian adults.

Resistance Training Arm (n=100): 3 supervised sessions per week (60 minutes per session) at 70-80% 1-repetition maximum (1RM) using progressive resistance overload reassessed every 8 weeks.

Control Arm (n=100): Standard individualized dietary and physical activity advice per national guidelines without supervised exercise sessions.

Outcome Assessments: Dual-energy X-ray absorptiometry (DEXA) for total LBM, appendicular lean mass, and body fat percentage; handgrip dynamometry and 1RM testing for strength; quantitative ELISA for serum biomarkers; real-time qRT-PCR (2-ΔΔCt method) for PBMC MSTN mRNA expression; and standardized biochemical panels for glycemic and inflammatory profiles.

Studietype

Ingrijpend

Inschrijving (Geschat)

200

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • National Capital Territory of Delhi
      • New Delhi, National Capital Territory of Delhi, Indië, 110016
        • Diabetes Foundation India
        • Contact:
        • Hoofdonderzoeker:
          • Professor Anoop Misra, MD
        • Onderonderzoeker:
          • Dr Surya Prakash Bhatt, PhD

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

35 jaar tot 60 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Age 35-60 years inclusive
  • BMI ≥ 25 kg/m² (Asian Indian cut-off for overweight)
  • Body fat percentage ≥ 30% in women or ≥ 25% in men measured by DEXA
  • Sedentary lifestyle, defined as less than 150 minutes per week of moderate-intensity physical activity by self-report and validated by wearable activity tracker at screening
  • Non-diabetic (fasting plasma glucose < 126 mg/dL and HbA1c < 6.5%)
  • Willing and able to provide written informed consent
  • Resident within 25 km of Fortis C-DOC for the full 12-month trial duration

Exclusion Criteria:

  • Known Type 2 Diabetes Mellitus
  • Established cardiovascular disease, heart failure, cerebrovascular accident, or peripheral arterial disease
  • Chronic kidney disease
  • Active malignancy or history of malignancy within 5 years
  • Use of anabolic steroids, systemic corticosteroids, growth hormone, or immunosuppressants within 3 months of enrolment
  • Any musculoskeletal, neurological, or orthopaedic condition precluding participation in supervised resistance training
  • Pregnancy or lactation
  • Participation in any structured supervised exercise programme in the preceding 6 months
  • HIV infection or other active chronic infection
  • Thyroid disorder not on stable replacement therapy for at least 3 months
  • Severe end-organ damage
  • Inability to provide informed consent

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Enkel

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Progressive Resistance Training

Supervised progressive resistance training program consisting of 3 sessions per week for 12 months (60 minutes per session) at 70-80% 1-repetition maximum (1RM). Includes multi-joint upper and lower body exercises (leg press, knee extension/flexion, hip abduction, lat pulldown, seated row, chest/overhead press, crunches) with formal load reassessment every 8 weeks.

12-month supervised progressive resistance training program, 3 sessions per week (60 min/session) at 70-80% 1-repetition maximum (1RM) featuring progressive overload reassessed every 8 weeks. Includes leg press, knee extension/flexion, hip abduction, lat pulldown, seated row, chest press, overhead press, and abdominal crunches.

A single 60-minute structured lifestyle counseling session at baseline providing individualized dietary and physical activity advice according to ICMR consensus guidelines for Asian Indians, supplemented with written educational materials.

Actieve vergelijker: Standard Lifestyle Advice

A single structured 60-minute lifestyle counseling session at baseline providing individualized dietary advice and physical activity recommendations based on ICMR national guidelines for Asian Indians, along with educational materials and follow-up assessments at 6 and 12 months.

12-month supervised progressive resistance training program, 3 sessions per week (60 min/session) at 70-80% 1-repetition maximum (1RM) featuring progressive overload reassessed every 8 weeks. Includes leg press, knee extension/flexion, hip abduction, lat pulldown, seated row, chest press, overhead press, and abdominal crunches.

A single 60-minute structured lifestyle counseling session at baseline providing individualized dietary and physical activity advice according to ICMR consensus guidelines for Asian Indians, supplemented with written educational materials.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percentage change in total lean body mass
Tijdsspanne: Baseline, 6 months, 12 months

Percentage change in total lean body mass (LBM) from baseline to 6 and 12 months measured by DEXA, comparing the resistance training and control groups and assessing differences between High-Ratio and Low-Ratio MSTN/FST strata.

Baseline, 6 months, 12 months
Change in Serum Myostatin Concentration
Tijdsspanne: Baseline, 12 months

Change in serum myostatin levels quantified in duplicate via validated sandwich ELISA (intra-assay CV < 8%, inter-assay CV < 10%).

Baseline, 12 months
Change in Serum Follistatin Concentration
Tijdsspanne: Baseline, 12 months

Change in serum follistatin levels quantified in duplicate via validated sandwich ELISA

Baseline, 12 months
Change in Serum Myostatin/Follistatin (MSTN/FST) Ratio
Tijdsspanne: Baseline, 12 months

Integrated dynamic index of anabolic-catabolic balance calculated as serum myostatin (pg/mL) divided by serum follistatin (pg/mL).

Baseline, 12 months
Change in PBMC MSTN mRNA Expression
Tijdsspanne: Baseline, 12 months

Relative gene expression of myostatin mRNA isolated from Peripheral Blood Mononuclear Cells (PBMCs) and measured via real-time quantitative PCR using the Livak 2 -ΔΔCT method normalized to GAPDH.

Baseline, 12 months
Change in Systemic Inflammatory Markers
Tijdsspanne: Baseline, 6 months, 12 months

Quantification of circulating serum Interleukin-6 (IL-6; pg/mL), Tumor Necrosis Factor-alpha (TNF-α; pg/mL), and high-sensitivity C-Reactive Protein (hsCRP; mg/L) via high-sensitivity immunoassay methods.

Baseline, 6 months, 12 months
Change in Skeletal Muscle Quality
Tijdsspanne: Baseline, 6 months, 12 months

Evaluation of muscle quality calculated as DEXA-derived muscle mass relative to strength, combined with ultrasound assessment of quadriceps muscle thickness and echo intensity.

Baseline, 6 months, 12 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Appendicular Lean Mass (ASMI)
Tijdsspanne: Baseline, 6-month, and 12-month.

Measured by DEXA (kg/m²)

Baseline, 6-month, and 12-month.
Handgrip Strength
Tijdsspanne: Baseline, 6-month, and 12-month.

Measured using a calibrated hand dynamometer (kg)

Baseline, 6-month, and 12-month.
Lower-Body Muscle Strength
Tijdsspanne: Baseline, 6-month, and 12-month.

Measured by 1-repetition maximum (1RM) in leg press (kg)

Baseline, 6-month, and 12-month.
Gait Speed
Tijdsspanne: Baseline, 6-month, and 12-month.

Measured by 4-metre timed walk test (seconds or m/s)

Baseline, 6-month, and 12-month.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Professor Anoop Misra, MD, Diabetes Foundation, India

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 december 2026

Primaire voltooiing (Geschat)

30 november 2029

Studie voltooiing (Geschat)

30 november 2029

Studieregistratiedata

Eerst ingediend

24 augustus 2026

Eerst ingediend dat voldeed aan de QC-criteria

18 november 2026

Eerst geplaatst (Werkelijk)

19 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

19 november 2026

Laatste update ingediend die voldeed aan QC-criteria

18 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren